NCT03215706 · OUTCOME

Time to Response (TTR)

A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC · Source last updated 2025-12-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: Months
Interval / dispersion: Full Range
Time frame: From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)

What was measured

TTR was defined as the time from randomization to the date of the first confirmed documented response (CR or PR), as assessed by the BICR. TTR was evaluated for responders (confirmed CR or PR) only.

Analysis population: All Confirmed Responders, Global Population

Groups in this outcome

Treatment A

Nivolumab + Ipilimumab + Chemotherapy

Treatment B

Chemotherapy only

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment A	137
Treatment B	90

Reported measurements

Source class 1

Values in Months · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Treatment A	2.53	Not reported	1.1	52.1	Not reported
Treatment B	1.58	Not reported	1.2	22.2	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
1.1
upper Limit
52.1
value
2.53
group Id
OG001
lower Limit
1.2
upper Limit
22.2
value
1.58

denoms

counts
group Id
OG000
value
137
group Id
OG001
value
90
units
Participants

description

TTR was defined as the time from randomization to the date of the first confirmed documented response (CR or PR), as assessed by the BICR. TTR was evaluated for responders (confirmed CR or PR) only.

dispersion Type

Full Range

groups

description
Nivolumab + Ipilimumab + Chemotherapy
id
OG000
title
Treatment A
description
Chemotherapy only
id
OG001
title
Treatment B

param Type

MEDIAN

population Description

All Confirmed Responders, Global Population

reporting Status

POSTED

time Frame

From date of randomization until date of documented tumor progression or death due to any cause, whichever occurs first (assessed up to October 2024, approximately 72 months)

title

Time to Response (TTR)

type

SECONDARY

unit Of Measure

Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice